---
schema_version: "secwatch.filing_event.v1"
accession: "0001108205-25-000022"
form_type: "8-K"
ticker: "CRIS"
cik: "0001108205"
company_name: "CURIS INC"
filed_at: "2025-03-28T23:59:59+00:00"
generated_at: "2026-05-24T02:54:24.054437+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Curis raises ~$10M; FY2024 net loss $43.4M; FDA/EMA see path for PCNSL drug

## Summary
- Gross proceeds ~$10M from sale of 1.97M shares and pre-funded warrants for 2.18M shares, plus common warrants for 8.32M shares at $2.41.
- FY2024 net loss $43.4M ($6.88/share) vs $47.4M in 2023; revenue $10.9M vs $10.0M; cash $20.0M at Dec 31, 2024.
- Cash runway extended into Q4 2025 with offering net proceeds combined with existing cash.
- FDA and CHMP guidance supports potential accelerated/conditional approval for emavusertib in PCNSL; 9 of 13 BTKi-experienced evaluable patients had tumor reduction with 4 CRs.

## SEC filing metadata
- accession: 0001108205-25-000022
- form_type: 8-K
- ticker: CRIS
- cik: 0001108205
- company_name: CURIS INC
- filed_at: 2025-03-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1108205/000110820525000022/0001108205-25-000022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1108205/000110820525000022/cris-20250328.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001108205-25-000022
- JSON: https://secwatch.observer/filing/0001108205-25-000022.json
- Plain text: https://secwatch.observer/filing/0001108205-25-000022.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.